<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Risk factors for cardiovascular disease in the kidney transplant recipient
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Risk factors for cardiovascular disease in the kidney transplant recipient
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Risk factors for cardiovascular disease in the kidney transplant recipient
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John Vella, MD, FACP, FRCP, FASN, FAST
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Krista L Lentine, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Daniel C Brennan, MD, FACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Albert Q Lam, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 13, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H197525625">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cardiovascular disease is the leading cause of morbidity and mortality after kidney transplantation. Death from cardiovascular disease is also the most common cause of graft loss.
        </p>
        <p>
         This topic reviews the risk factors for cardiovascular disease among kidney transplant recipients. The epidemiology of cardiovascular disease following transplantation, cardiovascular outcomes compared with dialysis patients, and the evaluation of kidney transplant candidates are discussed elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7347.html" rel="external">
          "Kidney transplantation in adults: Patient survival after kidney transplantation"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7309.html" rel="external">
          "Kidney transplantation in adults: Evaluation of the potential kidney transplant recipient"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2180381823">
         <span class="h1">
          OVERVIEW OF CARDIOVASCULAR RISK
         </span>
         <span class="headingEndMark">
          —
         </span>
         Transplant recipients have a lower risk of fatal and nonfatal cardiovascular events compared with waitlisted patients on dialysis [
         <a href="#rid1">
          1-4
         </a>
         ] but a much higher risk compared with the general population [
         <a href="#rid5">
          5
         </a>
         ]. Forty to 60 percent of posttransplant deaths with a reported cause are attributable to cardiovascular disease, with an incidence of ischemic heart disease of approximately 1 per 100 person-years at risk [
         <a href="#rid6">
          6-8
         </a>
         ]. Cardiovascular disease is the most common cause of death with graft function after transplant and accounts for 30 percent of graft loss from death overall, with the greatest rates early after transplant [
         <a href="#rid9">
          9
         </a>
         ]. Notably, the incidence of cardiovascular death after transplantation appears to be declining somewhat despite the aging and increased comorbidity burdens among transplant recipients, which may reflect advances in medical management or competing risks of cancer and infection [
         <a href="#rid10">
          10,11
         </a>
         ].
        </p>
        <p>
         The high rate of cardiovascular deaths in the transplant population is due in part to the large number of diabetic patients in the end-stage kidney disease (ESKD) population, who are at markedly increased cardiovascular risk compared with nondiabetic transplant recipients. As an example, in one study of 933 predominantly living-donor transplant recipients, cardiovascular disease was the most common cause of death among diabetic recipients; by contrast, most deaths among nondiabetic recipients were due to infection, malignancy, or other causes [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         However, the cardiovascular risk among transplant recipients who do not have ESKD related to diabetes is still higher than in the general population [
         <a href="#rid9">
          9
         </a>
         ]. The increased cardiovascular risk is due to the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An exacerbation of traditional risk factors present in the general population by immunosuppressive drugs (
         <a class="graphic graphic_figure graphicRef51988" href="/z/d/graphic/51988.html" rel="external">
          figure 1
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nontraditional risk factors related to immunosuppressive agents or to chronic kidney disease
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2704285919">
         <span class="h2">
          Coronary heart disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Traditional risk factors for coronary heart disease after kidney transplantation were investigated in a report of 403 patients who received 464 kidney transplants during a 10-year period [
         <a href="#rid13">
          13
         </a>
         ]. New atherosclerotic complications developed in 16 percent of patients. After accounting for pretransplant vascular disease, multivariate analysis revealed that the following risk factors were independently associated with posttransplant atherosclerotic cardiovascular disease:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increasing patient age
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diabetes mellitus
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Male sex
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cigarette smoking
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypertension
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elevated serum cholesterol
        </p>
        <p>
        </p>
        <p>
         Similar findings were observed in other studies [
         <a href="#rid14">
          14-16
         </a>
         ].
        </p>
        <p>
         Nontraditional risk factors that have been associated with increased cardiovascular risk in various studies include reduced kidney function following transplantation, dialysis vintage prior to transplantation, rejection, hyperhomocysteinemia, elevated levels of lipoprotein(a), elevated C-reactive protein and interleukin-6 levels, reduced homoarginine levels, proteinuria, and low levels of physical activity [
         <a href="#rid17">
          17-25
         </a>
         ].
        </p>
        <p>
         Although not directly linked to cardiovascular disease, the presence of vascular calcifications detected radiographically prior to transplantation (a common finding) is also associated with increased cardiovascular and all-cause mortality posttransplantation [
         <a href="#rid26">
          26,27
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7222.html" rel="external">
          "Vascular calcification in chronic kidney disease"
         </a>
         .)
        </p>
        <p>
         Individual risk factors are discussed below. (See
         <a class="local">
          'Individual risk factors'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1886824316">
         <span class="h2">
          Myocardial infarction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several studies have described the incidence and risk factors for myocardial infarction (MI) among kidney transplant recipients:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective study based upon the United States Renal Data System (USRDS) evaluated the clinical correlates of posttransplant MI [
         <a href="#rid1">
          1
         </a>
         ]. Among nearly 36,000 patients, the incidence of MI at 6, 12, and, 36 months was 4.3, 5.2, and 11.1 percent, respectively. The principal risk factors were increased age, recipient of kidneys from older donors and deceased donors, delayed allograft function, and the presence of pretransplant comorbidities, including diabetes, angina, peripheral vascular disease, and MI. The diagnosis of posttransplant diabetes and the development of allograft failure were also significantly associated with the development of an MI.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a similar study of 53,297 patients, a markedly increased risk of acute MI was observed early after transplantation, less than three months postsurgery [
         <a href="#rid28">
          28
         </a>
         ]. Compared with waitlist patients, the risk also varied by recipients of a deceased-donor kidney (relative risk [RR] 3.57, 95% CI 3.21-3.96) and living-donor kidney (RR 2.81, 95% CI 2.31-3.42).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective analysis of the placebo arm of the Assessment of LEscol in Renal Transplantation (ALERT) study, independent risk factors for nonfatal MI by multivariate analysis were preexisting coronary heart disease (hazard ratio [HR] 3.69), total cholesterol level (HR 1.55 per 50 mg/dL), and prior acute rejection (HR 2.36) [
         <a href="#rid15">
          15
         </a>
         ]. Age, diabetes, ST-T changes, and elevated serum creatinine levels were independent risk factors for cardiac death.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2096198880">
         <span class="h2">
          Heart failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cardiovascular disease includes both ischemic coronary heart disease and cardiomyopathy. Patients with ESKD, including transplant recipients, are at higher risk for both, compared with the general population. Cardiac endpoints are often pooled in epidemiologic studies, with the presumption that all reflect ischemic atherosclerotic disease [
         <a href="#rid5">
          5
         </a>
         ]. Some studies have examined the risk of specific cardiac endpoints among transplant recipients.
        </p>
        <p>
         Data on pretransplant heart failure (HF) prevalence and prognosis are limited, but the prevalence of HF with reduced ejection fraction in patients referred or wait-listed for transplantation may be as high as 25 percent [
         <a href="#rid4">
          4,29-32
         </a>
         ].
        </p>
        <p>
         Studies have shown that cardiomyopathy, either with or without clinical HF, is common among kidney transplant recipients. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective analysis of data derived from the USRDS showed that the cumulative incidence of new-onset HF was 10.2 and 18.3 percent at 12 and 36 months, respectively [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective study of 638 consecutive kidney transplant recipients who were free of cardiac disease at one year, new-onset HF occurred as frequently as new-onset ischemic heart disease (1.26 versus 1.22 events per 100 patient-years, respectively) [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The USRDS reports that HF is second only to infection as a cause of hospitalization after kidney transplantation [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Independent risk factors for new-onset HF after transplantation include age, diabetes, anemia, and hypertension [
         <a href="#rid4">
          4,18
         </a>
         ]. Studies of USRDS data have identified obesity, donor factors that may predict suboptimal graft function, and graft loss as risk factors for HF [
         <a href="#rid4">
          4,34
         </a>
         ].
        </p>
        <p>
         Obesity and smoking are associated with increased risk of HF [
         <a href="#rid4">
          4,29
         </a>
         ].
        </p>
        <p>
         Body mass index (BMI) was independently associated with HF in several USRDS registry studies [
         <a href="#rid4">
          4,35,36
         </a>
         ]. In one study, BMI ≥30 kg/m
         <sup>
          2
         </sup>
         predicted up to 59 percent RR increase, compared with BMI &lt;30 kg/m
         <sup>
          2
         </sup>
         [
         <a href="#rid35">
          35
         </a>
         ]. In another study of USRDS data, BMI &gt; 28.3 kg/m
         <sup>
          2
         </sup>
         independently predicted a 57 percent relative increase in the risk of hospitalized HF, compared with lower BMI [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
         A portion of obesity-related cardiovascular risk may be mediated by impacts on metabolic health including diabetes [
         <a href="#rid37">
          37
         </a>
         ]. A meta-analysis of six studies including 4111 patients demonstrated an increased risk of posttransplant diabetes mellitus associated with BMI &gt;30 compared with &lt;30 kg/m
         <sup>
          2
         </sup>
         (pooled RR 2.24, 95% CI 1.46-3.45).
        </p>
        <p>
         HF is associated with increased mortality after transplantation [
         <a href="#rid4">
          4,30
         </a>
         ]. In a single-center study, left ventricular systolic dysfunction, defined as left ventricular ejection fraction ≤45 percent by gated single photon emission computed tomography at the time of transplantation, was associated with 4.8 times the risk of cardiac death, 2 times the risk of all-cause mortality, and 1.8 times the risk of cardiac complications, compared with normal cardiac function [
         <a href="#rid30">
          30
         </a>
         ]. A study of USRDS data identified clinical diagnosis of new-onset HF after transplant as a potent predictor of subsequent death (adjusted HR [AHR] 2.6) [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2642988793">
         <span class="h2">
          Pulmonary hypertension
         </span>
         <span class="headingEndMark">
          —
         </span>
         Right HF and pulmonary hypertension at the time of transplantation have been associated with both delayed graft function and mortality [
         <a href="#rid38">
          38,39
         </a>
         ]. In a study of 215 potential kidney transplant candidates, estimated right ventricular systolic pressure ≥50 mmHg was associated with an increased risk of posttransplant death (HR 3.75) [
         <a href="#rid39">
          39
         </a>
         ]. Dialysis vintage was the strongest correlate of an elevated right ventricular systolic pressure. Among 739 transplant candidates assessed at a single center in New Zealand from 2000 to 2009, pulmonary hypertension and/or right ventricular dysfunction were independently associated with nearly twice the risk of all-cause mortality (AHR 1.91, 95% CI 1.28-2.83) over an average of 4.2 years after the echocardiographic evaluation in multivariate regression including age, diabetes, transplant listing status, severely impaired left ventricular ejection fraction, and presence of regional wall motion abnormalities [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
         Pulmonary hypertension in transplant candidates and recipients is generally a secondary, rather than idiopathic, process driven by left HF, high cardiac output from an arteriovenous fistula, hypoxic lung diseases, and metabolic derangements associated with kidney disease. Categorizing pulmonary hypertension according to underlying pathophysiologies, hemodynamic characteristics, and treatment responses as defined by the World Health Organization (WHO) can be challenging in this population but should be pursued to direct appropriate management [
         <a href="#rid41">
          41,42
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3270031278">
         <span class="h1">
          RISK STRATIFICATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cardiovascular risk stratification after kidney transplantation may be based upon traditional and nontraditional risk factors (see
         <a class="local">
          'Individual risk factors'
         </a>
         below), clinical parameters (eg, blood pressure), structural or functional parameters (eg, left ventricular hypertrophy), and biomarkers (eg, cardiac troponins) [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1516965258">
         <span class="h2">
          Framingham risk score
         </span>
         <span class="headingEndMark">
          —
         </span>
         The Framingham risk score is a composite index designed to predict coronary heart disease in the general population based upon traditional risk factors of age, sex, cholesterol levels, hypertension, and diabetes status. (See
         <a class="medical medical_review" href="/z/d/html/114029.html" rel="external">
          "Cardiovascular disease risk assessment for primary prevention: Risk calculators"
         </a>
         .)
        </p>
        <p>
         Although the Framingham risk score performs well in the general population, it generally underestimates the risk of cardiovascular events among kidney transplant patients [
         <a href="#rid17">
          17,44
         </a>
         ]. The individual Framingham risk factors are significantly associated with cardiovascular risk among kidney transplant recipients, but some effect sizes are increased among such patients.
        </p>
        <p>
         This prediction error is greatest among patients at highest risk and is driven in part by an underestimate of diabetes-related risk [
         <a href="#rid17">
          17,44
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective study of 1124 kidney transplant recipients with stable graft function at one year, the observed increase in risk conferred by diabetes was greater in transplant recipients compared with the Framingham Heart Study population (RRs of 2.8 versus 1.5, respectively, among men, and 5.4 versus 1.8, respectively, among women) [
         <a href="#rid44">
          44
         </a>
         ]. The risks conferred by age and smoking were also underestimated by the Framingham risk score, though to a lesser extent [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a historical cohort study of transplant recipients with functional allografts at one year, the Framingham risk score predicted only 59 percent of observed coronary events [
         <a href="#rid17">
          17
         </a>
         ]. This was entirely due to an underestimate among high-risk patients (defined as greater than 20 percent risk of event at 10 years according to the Framingham heart score). The risk score performed well among low-risk patients (less than 20 percent risk at 10 years).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a prospective cohort study of 540 transplant recipients, the Framingham risk score underestimated cardiac events but not stroke, with ratios of observed-to-predicted cardiac events of 1.64 and 0.96, respectively [
         <a href="#rid45">
          45
         </a>
         ]. As noted in the previous study, the risk score performed least well among the highest risk patients; subgroup analysis showed higher observed-to-predicted cardiac event ratios among patients with pretransplant diabetes, prior cardiac disease, or both (2.12, 2.00, and 2.74, respectively).
        </p>
        <p>
        </p>
        <p>
         Others composite risk scores have been developed for the transplant population, but only a few have been externally validated [
         <a href="#rid46">
          46,47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1228809984">
         <span class="h2">
          Cardiac troponins
         </span>
         <span class="headingEndMark">
          —
         </span>
         Measurement of cardiac troponins may allow more accurate cardiovascular risk stratification than is provided by currently available methods. Persistent elevations in cardiac troponins may result from volume overload, uncontrolled hypertension, or left ventricular hypertrophy, all which confer a higher risk of cardiovascular events [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
         As an example, in a single-center retrospective cohort study, elevated troponin T concentrations prior to transplantation (measured at the initial pretransplant evaluation and then annually for patients on the waiting list) were independently associated with posttransplantation cardiac events and death [
         <a href="#rid49">
          49
         </a>
         ]. Over a mean follow-up of 28 months, troponin T concentrations of 0.01 to 0.03, 0.04 to 0.1, and greater than 0.10 ng/mL were associated with increased relative risks (RRs) of major adverse cardiac events after transplantation (hazard ratios [HRs] 2.52, 4.48, and 6.12, respectively).
        </p>
        <p>
         In a prospective observational study of 331 kidney or kidney-pancreas recipients, each 0.01 mcg/L increase in troponin I measured at the time of transplantation was associated on multivariate analysis with a 17 percent increase in the risk of major adverse cardiac events within three months after transplantation (adjusted odds ratio [OR] 1.17) [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
         It remains uncertain how biomarker assessment should be used to direct therapies or subsequent diagnostic testing before or after kidney transplantation. Measurement of cardiac troponin concentrations in transplant recipients may be considered as an additional prognostic marker.
        </p>
        <p class="headingAnchor" id="H3803867342">
         <span class="h1">
          RISK REDUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The reduction of cardiovascular risk requires the accurate assessment of risk in transplant candidates and the appropriate pharmacologic and nonpharmacologic interventions. (See
         <a class="local">
          'Individual risk factors'
         </a>
         below.)
        </p>
        <p>
         A reduction in cardiovascular risk may be achieved through appropriate medical therapies.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7573.html" rel="external">
          "Overview of primary prevention of cardiovascular disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">
          "Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">
          "Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/110006.html" rel="external">
          "Aspirin for the secondary prevention of atherosclerotic cardiovascular disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         There is considerable practice variation in the use of potentially cardioprotective medications in kidney transplant recipients, even among patients considered to be at high risk based upon preexisting diabetes or cardiovascular disease. Studies suggest that primary and secondary cardiovascular preventive measures are underutilized among transplant recipients [
         <a href="#rid51">
          51-53
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The Long-Term Deterioration of Kidney Allograft Function (DeKAF) study, a multicenter, prospective, observational study of transplant recipients, revealed that fewer than 30 percent of participating transplant recipients with preexisting cardiovascular disease or diabetes received angiotensin-converting enzyme (ACE) inhibitor/angiotensin-II receptor blocker (ARB) therapy at six months posttransplant; fewer than 60 percent received
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         ; and one-half received a statin [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Predicting Outcomes in Renal Transplantation (PORT), a multicenter, collaborative database investigation of nonimmunosuppressive medication use, found no difference in the use of most cardiovascular medications between diabetic and nondiabetic patients. Although the use of multiple cardiovascular medications was higher in patients with a previous cardiovascular event compared with patients with no previous cardiovascular disease, fewer than 75 percent of patients with previous cardiovascular disease were using a statin or antiplatelet agent [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of integrated Organ Procurement and Transplantation Network (OPTN) registry and pharmacy billing claims data to characterize cardiovascular medication prescriptions early after myocardial infarction (MI) showed that, within the first 60 days after acute MI (AMI), prescriptions for beta blockers, antiplatelet agents, ACE inhibitors/ARBs, and statins were submitted in only 83, 48, 65, and 72 percent, respectively, which was roughly comparable with nontransplant patients matched by demographic and measured clinical characteristics [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Linked OPTN and pharmacy data from 2005 to 2010 demonstrated that approximately 18 to 25 percent of kidney transplant recipients were treated with an ACE inhibitor/ARB, and 25 to 45 percent received a statin at one year posttransplant, depending upon kidney function and immunosuppressive regimen [
         <a href="#rid54">
          54,55
         </a>
         ]. These data also suggest variation with immunosuppression regimen. Compared with those taking triple immunosuppression, recipients taking tacrolimus-based dual- and monotherapies had lower use of statins and ACE inhibitors/ARBs.
        </p>
        <p>
        </p>
        <p>
         While there may be legitimate reasons for not prescribing potentially cardioprotective medications in transplanted patients (eg, allograft dysfunction, hyperkalemia, and anemia may limit use of ACE inhibitors/ARBs), these studies suggest potential room for improvement in the treatment of cardiovascular risks among high-risk transplant recipients.
        </p>
        <p class="headingAnchor" id="H552744375">
         <span class="h1">
          INDIVIDUAL RISK FACTORS
         </span>
        </p>
        <p class="headingAnchor" id="H3735403508">
         <span class="h2">
          Traditional risk factors
         </span>
        </p>
        <p class="headingAnchor" id="H2508394848">
         <span class="h3">
          Pretransplant cardiovascular disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pretransplant cardiovascular disease continues to be the most important predictor of posttransplant cardiovascular events [
         <a href="#rid13">
          13,56,57
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H275679087">
         <span class="h3">
          Dyslipidemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite advances in short-term allograft survival due to improvements in immunosuppressive regimens, dyslipidemia remains a significant problem in the transplant population. Glucocorticoids,
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         , and, to a lesser extent,
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         increase serum triglyceride and cholesterol concentrations. This is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7303.html" rel="external">
          "Lipid abnormalities after kidney transplantation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4162795756">
         <span class="h3">
          Blood pressure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypertension is a well-known risk factor for cardiovascular disease and stroke in both the general population and transplant recipients due in part to its association with left ventricular hypertrophy. (See
         <a class="medical medical_review" href="/z/d/html/3850.html" rel="external">
          "Cardiovascular risks of hypertension"
         </a>
         .)
        </p>
        <p>
         The association of high systolic blood pressures with cardiovascular disease among transplant recipients has been shown in post hoc analyses of two randomized trials [
         <a href="#rid58">
          58,59
         </a>
         ]. In an analysis of data from the
         <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">
          Folic Acid
         </a>
         for Vascular Outcomes Reduction in Transplantation (FAVORIT) trial, each 20 mmHg increase in systolic pressure was associated with an increased risk of cardiovascular disease (hazard ratio [HR] 1.32, 95% CI 1.19-1.46) and mortality (HR 1.13, 95% CI 1.01-1.27) [
         <a href="#rid58">
          58
         </a>
         ]. At diastolic blood pressures of &lt;70 mmHg, each 10 mmHg
         <strong>
          decrease
         </strong>
         in diastolic blood pressure was associated with increased risk of cardiovascular disease (HR 1.31, 95% CI 1.06-1.62) and mortality (HR 1.31, 95% CI 1.03-1.66). However, virtually all participants had kidney function impairment, which may limit the generalizability of observations [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
         Reinforcing the outcome implications of low blood pressure, an analysis of integrated national transplant registry, pharmacy fill, and medical claims data found that pretransplant
         <a class="drug drug_general" data-topicid="9651" href="/z/d/drug information/9651.html" rel="external">
          midodrine
         </a>
         use, an indicator of symptomatic hypotension, also predicted posttransplant complications [
         <a href="#rid61">
          61
         </a>
         ]. Midodrine use in the year before transplant was associated with increased adjusted risks of delayed graft function, hypotension, acute myocardial infarction (AMI), cardiac arrest, graft failure, and death over the first year posttransplant.
        </p>
        <p>
         The immunosuppressive agents that can cause new-onset hypertension or exacerbate preexisting hypertension include calcineurin inhibitors and, to a lesser extent, because of rapid dose reduction, corticosteroids.
        </p>
        <p>
         Details concerning these issues and the management of hypertension in kidney transplant recipients are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7360.html" rel="external">
          "Hypertension after kidney transplantation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2670741992">
         <span class="h3">
          Diabetes mellitus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both pretransplant and posttransplant diabetes mellitus are associated with the risk of posttransplant cardiovascular complications such as MI and heart failure (HF) [
         <a href="#rid1">
          1,4
         </a>
         ]. Antirejection medications that contribute to posttransplant diabetes mellitus include glucocorticoids, calcineurin inhibitors, and mammalian (mechanistic) target of rapamycin (mTOR) inhibitors, although risk may be modified by other factors such as age and body mass index (BMI) [
         <a href="#rid62">
          62
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7327.html" rel="external">
          "Kidney transplantation in adults: Posttransplantation diabetes mellitus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3092643222">
         <span class="h3">
          Chronic kidney disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         As observed among nontransplanted patients, kidney function impairment in kidney transplant patients is a significant risk factor for adverse cardiovascular outcomes [
         <a href="#rid23">
          23,35,63
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/7190.html" rel="external">
          "Chronic kidney disease and coronary heart disease"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among nearly 60,000 patients in one registry study, there was a graded increase in the risk of cardiac death with serum creatinine levels above 1.5 mg/dL (133 micromol/L) at one year posttransplant, up to more than twice the relative risk (RR) among those with serum creatinine levels 2.6 to 4.0 mg/dL compared with &lt;1.5 mg/dL (adjusted HR [AHR] 2.6) [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a second registry study of almost 30,000 kidney transplant recipients, a decreased estimated glomerular filtration rate (eGFR) of &lt;45 mL/min/1.73 m
         <sup>
          2
         </sup>
         at one year posttransplant correlated with increased risk of acute coronary syndrome (AHR 2.2) and HF (AHR 2.95) [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among over 1000 placebo-treated patients in the Assessment of LEscol in Renal Transplantation (ALERT) trial, an increased serum creatinine concentration, particularly higher than 2.3 mg/dL (200 micromol/L), was strongly associated with an increased risk of adverse cardiac events and cardiac death [
         <a href="#rid63">
          63,64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a post hoc analysis of data for 3511 prevalent kidney transplant recipients in the FAVORIT trial, cardiovascular event rates over four years were higher among those with both lower eGFRs and higher urinary albumin-to-creatinine ratios at randomization [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1548105430">
         <span class="h3">
          Obesity and the metabolic syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         The epidemic of obesity in the United States has not spared kidney transplant candidates. Obesity trends in transplant recipients tend to mimic the general population (see
         <a class="medical medical_review" href="/z/d/html/5372.html" rel="external">
          "Obesity in adults: Prevalence, screening, and evaluation"
         </a>
         ). While less than 20 percent of candidates were classified as having any level of obesity (BMI &gt;30 kg/m
         <sup>
          2
         </sup>
         ) in the 1990s, in 2011, 23 percent of United States recipients were classified with class I obesity (BMI 30 to 34.9 kg/m
         <sup>
          2
         </sup>
         ), 9.4 percent with class II obesity (BMI 35 to 39.9 kg/m
         <sup>
          2
         </sup>
         ), and 2.1 percent with class III obesity (BMI &gt;40 kg/m
         <sup>
          2
         </sup>
         ) [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
         Weight gain after transplant is common and may be related to improved appetite with reversal of uremia and relatively high glucocorticoid doses in the peritransplant period but is also associated with physical inactivity [
         <a href="#rid67">
          67
         </a>
         ]. Obesity among transplant recipients is frequently associated with the metabolic syndrome. The metabolic syndrome was identified among 63 percent of 606 kidney transplant recipients assessed at a median of six years posttransplant at one center [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
         Obesity increases the risk of cardiovascular disease in the general population (see
         <a class="medical medical_review" href="/z/d/html/1529.html" rel="external">
          "Obesity: Association with cardiovascular disease"
         </a>
         ). Among kidney transplant recipients, the presence of obesity, particularly in association with the metabolic syndrome, also appears to be associated with an increased number of adverse cardiovascular events. In one study of 337 kidney transplant recipients, one-third had metabolic syndrome by the first transplant anniversary, whereas only 20 percent had metabolic syndrome before transplant [
         <a href="#rid69">
          69
         </a>
         ]. Over eight years of follow-up, 42 percent of the sample developed atherosclerotic disease events, and the risk of these events was significantly increased among patients with metabolic syndrome by one year after transplant (HR 3.4, 95% CI 1.6-7.3).
        </p>
        <p>
         High BMI has also been associated with an increased risk of cardiac death after kidney transplantation. In a study of nearly 52,000 patients in the United States Renal Data System (USRDS) registry, the adjusted risk of cardiac death increased at both low BMI (AHR 1.3 for BMI of &lt;20 kg/m
         <sup>
          2
         </sup>
         ) and high BMI (AHR 1.2 for BMI 30 to 32 kg/m
         <sup>
          2
         </sup>
         ; AHR 1.4 for BMI &gt;36 kg/m
         <sup>
          2
         </sup>
         ), compared with the reference group with BMI 22 to 24 kg/m
         <sup>
          2
         </sup>
         [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
         Obesity also increases the risk of HF and atrial fibrillation. As an example, in a single-center study, the five-year incidence of cardiac diagnoses increased from 9 to 30 percent as the BMI quartiles increased from the lowest to highest [
         <a href="#rid29">
          29
         </a>
         ]. This was largely due to increases in the incidence of HF and atrial fibrillation.
        </p>
        <p>
         BMI was independently associated with increased risk of HF and atrial fibrillation in several USRDS registry studies [
         <a href="#rid4">
          4,35,36
         </a>
         ]. As an example, BMI ≥30 kg/m
         <sup>
          2
         </sup>
         predicted up to 59 percent RR increase compared with BMI &lt; 30 kg/m
         <sup>
          2
         </sup>
         [
         <a href="#rid35">
          35
         </a>
         ]. In other studies of USRDS data, BMI &gt; 28 kg/m
         <sup>
          2
         </sup>
         independently predicted a 57 and 79 percent relative increase in the risk of hospitalized HF and atrial fibrillation, respectively, compared with lower BMI [
         <a href="#rid34">
          34,36
         </a>
         ].
        </p>
        <p>
         Lifestyle changes based in diet and exercise, with supervision by a kidney dietician as needed, are first-line strategies to achieve and maintain normal body weight among obese transplant recipients [
         <a href="#rid71">
          71
         </a>
         ]. Cases of bariatric surgery among transplant recipients with obesity have been reported [
         <a href="#rid72">
          72
         </a>
         ], but surgical therapies warrant prospective evaluation to quantify risks and benefits in this population.
        </p>
        <p class="headingAnchor" id="H2025282220">
         <span class="h3">
          Smoking
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the general and transplant populations, smoking increases the risk of cardiovascular disease [
         <a href="#rid73">
          73,74
         </a>
         ]. Among transplant recipients, smoking has been independently associated with the risk of death with graft function [
         <a href="#rid74">
          74
         </a>
         ], all-cause mortality [
         <a href="#rid75">
          75
         </a>
         ], and events such as HF [
         <a href="#rid4">
          4
         </a>
         ], ischemic stroke [
         <a href="#rid3">
          3
         </a>
         ], and new-onset cardiovascular disease after transplant [
         <a href="#rid75">
          75
         </a>
         ]. With smoking cessation, the increased risk dissipates over time [
         <a href="#rid73">
          73
         </a>
         ]. We recommend complete smoking cessation, with the adoption of measures to encourage smoking cessation.
        </p>
        <p>
         Unfortunately, no clinical trial data address the safety and utility of pharmacologic interventions to promote smoking cessation in the transplant population:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">
          Nicotine
         </a>
         replacement options probably carry little risk and may promote successful cessation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The use of
         <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">
          varenicline
         </a>
         may be problematic in kidney allograft recipients with poor kidney function as this drug is renally excreted. Dosing of this agent in those with decreased kidney function is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">
          "Overview of smoking cessation management in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2128740941">
         <span class="h3">
          Albuminuria
         </span>
         <span class="headingEndMark">
          —
         </span>
         As in the general population, albuminuria appears to be a risk factor for cardiovascular disease in kidney transplant recipients. A post hoc analysis of data from the FAVORIT trial found that, compared with urinary albumin-to-creatinine ratio &lt;10 mg/g at randomization, urinary albumin-to-creatinine ratios of 30 to 299 and ≥300 mg/g were independently associated with an increased risk of major adverse cardiac events (HRs 1.25, 95% CI 0.96-1.61, and 1.55, 95% CI 1.13-2.11, respectively), graft failure (HRs 3.40, 95% CI 2.19-5.30, and 9.96, 95% CI 6.35-15.62, respectively), and all-cause death (HRs 1.65, 95% CI 1.23-2.21, and 2.07, 95% CI 1.46-2.94, respectively) over four years [
         <a href="#rid65">
          65
         </a>
         ]. Similarly, among 1069 kidney transplant recipients in Canada, over a median follow-up of six years, the adjusted rate of all-cause mortality and cardiovascular events was 2.7-fold higher for recipients with an eGFR of 15 to 29 mL/min/1.73 m
         <sup>
          2
         </sup>
         and heavy albuminuria (&gt;300 mg/g) compared with recipients with an eGFR ≥60 mL/min/1.73 m
         <sup>
          2
         </sup>
         and normal albuminuria (rate ratio 2.7, 95% CI 1.3-5.7) [
         <a href="#rid76">
          76
         </a>
         ]. Recipients with heavy albuminuria had a threefold increased risk of all-cause mortality and HF compared with recipients with eGFR ≥60 mL/min/1.73 m
         <sup>
          2
         </sup>
         and normal albuminuria.
        </p>
        <p class="headingAnchor" id="H9347609">
         <span class="h2">
          Other risk factors
         </span>
        </p>
        <p class="headingAnchor" id="H82658656">
         <span class="h3">
          Anemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anemia defined by World Health Organization (WHO) criteria affects up to 30 to 40 percent of kidney transplant recipients [
         <a href="#rid77">
          77,78
         </a>
         ]. Posttransplant anemia has been correlated with the risk of subsequent cardiovascular complications such as HF [
         <a href="#rid4">
          4
         </a>
         ] and atrial fibrillation [
         <a href="#rid79">
          79
         </a>
         ], as well as with increased risk of posttransplant graft loss and patient death [
         <a href="#rid80">
          80,81
         </a>
         ].
        </p>
        <p>
         Recommendations regarding the management of posttransplant anemia are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7330.html" rel="external">
          "Anemia and the kidney transplant recipient"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H718479809">
         <span class="h3">
          Hyperhomocysteinemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Homocysteine is a nonessential amino acid that is an intermediate in the synthesis of cysteine and a precursor of the essential amino acid, methionine. Since homocysteine is normally cleared by the kidneys, serum concentrations are increased in chronic kidney disease [
         <a href="#rid82">
          82
         </a>
         ]. Hyperhomocysteinemia is also caused by an absolute or relative deficiency of vitamins B6, B12, and folate, all of which are involved in methionine metabolism and by defects in the methylene tetrahydrofolate reductase enzyme. (See
         <a class="medical medical_review" href="/z/d/html/6837.html" rel="external">
          "Overview of homocysteine"
         </a>
         .)
        </p>
        <p>
         The presence of elevated homocysteine levels in peripheral venous blood has been identified as an independent risk factor for ischemic heart disease and stroke in the general population, as well as being a predictor of mortality in patients with coronary heart disease in some studies [
         <a href="#rid83">
          83
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6837.html" rel="external">
          "Overview of homocysteine", section on 'Disease associations'
         </a>
         .)
        </p>
        <p>
         This association has also been found among kidney transplant recipients [
         <a href="#rid17">
          17,84,85
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one prospective study of 207 stable patients, fasting mean total homocysteine levels were significantly higher among patients who experienced a cardiovascular event at follow-up of 21 months (32 versus 18 micromol/L for those without such an event) [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among 733 kidney transplant recipients during a six-year period, elevated homocysteine levels were associated with 2.44 times the mortality risk of patients with normal levels (HR 2.44, 95% CI 1.45-4.12) [
         <a href="#rid85">
          85
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Effective reduction in serum homocysteine levels in kidney transplant recipients may be obtained with the administration of
         <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">
          folic acid
         </a>
         and vitamins B6 and B12 [
         <a href="#rid86">
          86
         </a>
         ]. However, although hyperhomocysteinemia is an independent risk factor for cerebrovascular, peripheral vascular, and coronary heart disease, lowering homocysteine levels has not been shown to decrease cardiovascular risk in kidney transplant recipients. As an example, the multicenter randomized trial FAVORIT showed no reduction in all-cause mortality, end-stage kidney disease (ESKD), or in a composite outcome including cardiovascular death, MI, resuscitated sudden death, stroke, revascularization, amputation, or aortic aneurysm repair among 4110 kidney transplant recipients treated with
         <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">
          vitamin B6
         </a>
         and
         <a class="drug drug_general" data-topicid="9302" href="/z/d/drug information/9302.html" rel="external">
          vitamin B12
         </a>
         and with either high- or low-dose folic acid, despite the fact that homocysteine was effectively lowered with high-dose folic acid [
         <a href="#rid87">
          87
         </a>
         ]. Based upon this study, a 2015 Cochrane review concluded that there is no evidence to support the use of homocysteine-lowering therapy for cardiovascular disease prevention in kidney transplant recipients [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1289785804">
         <span class="h3">
          Homoarginine deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Homoarginine is a lysine-derived amino acid that is primarily synthesized in the kidney and increases intracellular concentrations of L-arginine, which is the main substrate for nitric oxide (NO) synthase [
         <a href="#rid89">
          89
         </a>
         ]. Homoarginine may decrease endothelial injury and cardiovascular risk, and homoarginine deficiency may increase cardiovascular risk. In a post hoc analysis of the ALERT trial, among kidney transplant recipients who were randomly assigned to the placebo arm (n = 829), at an average of 6.7 years of follow-up, compared with those in the highest homoarginine quartile (&gt;2.34 micromol), patients in the lowest quartile (&lt;1.40 micromol/L) had 2.6 times increased risk of cerebrovascular events (AHR 2.56, 95% CI 1.13-5.82) and 2.3 times increased risk of graft loss or doubling of serum creatinine (AHR 2.34, 95% CI 1.36-4.02) [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         Compared with the highest homoarginine quartile, the lowest and second homoarginine quartiles were associated with increased risks of noncardiovascular mortality, while the lowest quartile was associated with 2.5 times the risk of all-cause mortality (AHR 2.50, 95% CI 1.38-4.55). Otherwise, risks did not differ significantly for the second and third compared with the highest quartile, and there were no significant associations of homoarginine levels with major adverse cardiovascular events or nonfatal MI. Another study of 704 kidney transplant recipients found an inverse association of higher urinary homoarginine with lower all-cause mortality and graft failure over an average of three years [
         <a href="#rid90">
          90
         </a>
         ]. Further research is needed to determine whether homoarginine supplementation modifies cardiovascular risk in this population.
        </p>
        <p class="headingAnchor" id="H2854134015">
         <span class="h3">
          Hyperphosphatemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyperphosphatemia has been associated with a higher risk of cardiovascular disease in kidney transplant patients. In a post hoc analysis of data for 3138 kidney transplant recipients participating in the FAVORIT trial, a 1 mg/dL higher serum phosphorus level was associated with a significant increase in the risk of major adverse cardiac events (HR 1.14, 95% CI 1.00-1.31), transplant failure (HR 1.72, 95% CI 1.46-2.01), and mortality (HR 1.34, 95% CI 1.15-1.54) over four years, after adjustment for trial treatment allocation, traditional cardiovascular risk factors, type of kidney transplant, transplant vintage, and use of calcineurin inhibitors, glucocorticoids, and lipid-lowering drugs [
         <a href="#rid91">
          91
         </a>
         ]. Associations were attenuated after adjustment including eGFR and albuminuria: cardiovascular events (HR 1.06, 95% CI 0.92-1.22), transplant failure (HR 1.36, 95% CI 1.15-1.62), and total mortality (HR 1.21, 95% CI 1.04-1.40).
        </p>
        <p class="headingAnchor" id="H1815981148">
         <span class="h3">
          Dialysis vintage
         </span>
         <span class="headingEndMark">
          —
         </span>
         Increasing dialysis vintage prior to transplantation is associated with a graded increase in the risk of cardiovascular death after transplant [
         <a href="#rid23">
          23
         </a>
         ]. A likely explanation for this is that accelerated atherogenesis is observed as part of the uremic syndrome. Proatherogenic factors that contribute to the progression of vascular disease prior to transplantation may include anemia, abnormalities of mineral metabolism, dyslipidemia [
         <a href="#rid92">
          92
         </a>
         ], and hyperhomocysteinemia [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
         These factors become increasingly important with the onset of chronic allograft dysfunction that leads to progressive uremia. (See
         <a class="medical medical_review" href="/z/d/html/7302.html" rel="external">
          "Kidney transplantation in adults: Risk factors for graft failure"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3788525545">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         – Cardiovascular disease is the leading cause of morbidity and mortality after kidney transplantation. Death from cardiovascular disease is also the most common cause of graft loss. Transplant recipients have a lower risk of fatal and nonfatal cardiovascular events compared with waitlisted patients on dialysis but a much higher risk compared with the general population. The high rate of cardiovascular deaths in the transplant population is due in part to the large number of patients with diabetes in the end-stage kidney disease (ESKD) population, who are at markedly increased cardiovascular risk compared with transplant recipients without diabetes. (See
         <a class="local">
          'Overview of cardiovascular risk'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk stratification
         </strong>
         – The Framingham risk score underestimates the risk of cardiovascular events among kidney transplant patients. Although the individual Framingham risk factors are significantly associated with cardiovascular risk among kidney transplant recipients, the effect sizes are increased among such patients, especially among patients at highest risk. (See
         <a class="local">
          'Framingham risk score'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk reduction
         </strong>
         – The reduction of cardiovascular risk requires the accurate assessment of risk in transplant candidates and the appropriate pharmacologic and nonpharmacologic interventions. (See
         <a class="local">
          'Risk reduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Traditional risk factors
         </strong>
         – Traditional risk factors present in the general population also exist in kidney transplant recipients. These factors include pretransplant cardiovascular disease, dyslipidemia, hypertension, diabetes mellitus, chronic kidney disease, obesity and the metabolic syndrome, smoking, and albuminuria. Some of these factors may be exacerbated by immunosuppressive medications. (See
         <a class="local">
          'Traditional risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other risk factors
         </strong>
         – Other nontraditional risk factors present in kidney transplant recipients include posttransplant anemia, hyperhomocysteinemia, homoarginine deficiency, hyperphosphatemia, and dialysis vintage. (See
         <a class="local">
          'Other risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 2005; 16:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant 2004; 4:1662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lentine KL, Rocca Rey LA, Kolli S, et al. Variations in the risk for cerebrovascular events after kidney transplant compared with experience on the waiting list and after graft failure. Clin J Am Soc Nephrol 2008; 3:1090.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lentine KL, Schnitzler MA, Abbott KC, et al. De novo congestive heart failure after kidney transplantation: a common condition with poor prognostic implications. Am J Kidney Dis 2005; 46:720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jardine AG, Gaston RS, Fellstrom BC, Holdaas H. Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet 2011; 378:1419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeo FE, Villines TC, Bucci JR, et al. Cardiovascular risk in stage 4 and 5 nephropathy. Adv Chronic Kidney Dis 2004; 11:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006; 82:603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Awan AA, Niu J, Pan JS, et al. Trends in the Causes of Death among Kidney Transplant Recipients in the United States (1996-2014). Am J Nephrol 2018; 48:472.
          </a>
         </li>
         <li class="breakAll">
          US Renal Data System. USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD 2008.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pippias M, Jager KJ, Kramer A, et al. The changing trends and outcomes in renal replacement therapy: data from the ERA-EDTA Registry. Nephrol Dial Transplant 2016; 31:831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lam NN, Kim SJ, Knoll GA, et al. The Risk of Cardiovascular Disease Is Not Increasing Over Time Despite Aging and Higher Comorbidity Burden of Kidney Transplant Recipients. Transplantation 2017; 101:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cosio FG, Hickson LJ, Griffin MD, et al. Patient survival and cardiovascular risk after kidney transplantation: the challenge of diabetes. Am J Transplant 2008; 8:593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kasiske BL. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med 1988; 84:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Mattos AM, Prather J, Olyaei AJ, et al. Cardiovascular events following renal transplantation: role of traditional and transplant-specific risk factors. Kidney Int 2006; 70:757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jardine AG, Fellström B, Logan JO, et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. Am J Kidney Dis 2005; 46:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vanrenterghem YF, Claes K, Montagnino G, et al. Risk factors for cardiovascular events after successful renal transplantation. Transplantation 2008; 85:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ducloux D, Kazory A, Chalopin JM. Predicting coronary heart disease in renal transplant recipients: a prospective study. Kidney Int 2004; 66:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rigatto C, Parfrey P, Foley R, et al. Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol 2002; 13:1084.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abbott KC, Bucci JR, Cruess D, et al. Graft loss and acute coronary syndromes after renal transplantation in the United States. J Am Soc Nephrol 2002; 13:2560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jindal RM, Zawada ET Jr. Obesity and kidney transplantation. Am J Kidney Dis 2004; 43:943.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dussol B, Bonnet JL, Sampol J, et al. Prognostic value of inducible myocardial ischemia in predicting cardiovascular events after renal transplantation. Kidney Int 2004; 66:1633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abedini S, Holme I, März W, et al. Inflammation in renal transplantation. Clin J Am Soc Nephrol 2009; 4:1246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75:1291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zelle DM, Corpeleijn E, Stolk RP, et al. Low physical activity and risk of cardiovascular and all-cause mortality in renal transplant recipients. Clin J Am Soc Nephrol 2011; 6:898.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drechsler C, Pihlstrøm H, Meinitzer A, et al. Homoarginine and Clinical Outcomes in Renal Transplant Recipients: Results From the Assessment of Lescol in Renal Transplantation Study. Transplantation 2015; 99:1470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosas SE, Mensah K, Weinstein RB, et al. Coronary artery calcification in renal transplant recipients. Am J Transplant 2005; 5:1942.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hernández D, Rufino M, Bartolomei S, et al. Clinical impact of preexisting vascular calcifications on mortality after renal transplantation. Kidney Int 2005; 67:2015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kasiske BL, Maclean JR, Snyder JJ. Acute myocardial infarction and kidney transplantation. J Am Soc Nephrol 2006; 17:900.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lentine KL, Rocca-Rey LA, Bacchi G, et al. Obesity and cardiac risk after kidney transplantation: experience at one center and comprehensive literature review. Transplantation 2008; 86:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siedlecki A, Foushee M, Curtis JJ, et al. The impact of left ventricular systolic dysfunction on survival after renal transplantation. Transplantation 2007; 84:1610.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu C, Evans I, Joseph R, et al. Comorbid conditions in kidney transplantation: association with graft and patient survival. J Am Soc Nephrol 2005; 16:3437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faravardeh A, Eickhoff M, Jackson S, et al. Predictors of graft failure and death in elderly kidney transplant recipients. Transplantation 2013; 96:1089.
          </a>
         </li>
         <li class="breakAll">
          US Renal Data System, USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2007.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abbott KC, Hypolite IO, Hshieh P, et al. Hospitalized congestive heart failure after renal transplantation in the United States. Ann Epidemiol 2002; 12:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abbott KC, Yuan CM, Taylor AJ, et al. Early renal insufficiency and hospitalized heart disease after renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 2003; 14:2358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abbott KC, Reynolds JC, Taylor AJ, Agodoa LY. Hospitalized atrial fibrillation after renal transplantation in the United States. Am J Transplant 2003; 3:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lafranca JA, IJermans JN, Betjes MG, Dor FJ. Body mass index and outcome in renal transplant recipients: a systematic review and meta-analysis. BMC Med 2015; 13:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zlotnick DM, Axelrod DA, Chobanian MC, et al. Non-invasive detection of pulmonary hypertension prior to renal transplantation is a predictor of increased risk for early graft dysfunction. Nephrol Dial Transplant 2010; 25:3090.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Issa N, Krowka MJ, Griffin MD, et al. Pulmonary hypertension is associated with reduced patient survival after kidney transplantation. Transplantation 2008; 86:1384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stallworthy EJ, Pilmore HL, Webster MW, et al. Do echocardiographic parameters predict mortality in patients with end-stage renal disease? Transplantation 2013; 95:1225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lentine KL, Villines TC, Axelrod D, et al. Evaluation and Management of Pulmonary Hypertension in Kidney Transplant Candidates and Recipients: Concepts and Controversies. Transplantation 2017; 101:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rangaswami J, Bhalla V, Blair JEA, et al. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. Circulation 2019; 139:e840.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarnak MJ, Amann K, Bangalore S, et al. Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review. J Am Coll Cardiol 2019; 74:1823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11:1735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kiberd B, Panek R. Cardiovascular outcomes in the outpatient kidney transplant clinic: the Framingham risk score revisited. Clin J Am Soc Nephrol 2008; 3:822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Israni AK, Snyder JJ, Skeans MA, et al. Predicting coronary heart disease after kidney transplantation: Patient Outcomes in Renal Transplantation (PORT) Study. Am J Transplant 2010; 10:338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soveri I, Snyder J, Holdaas H, et al. The external validation of the cardiovascular risk equation for renal transplant recipients: applications to BENEFIT and BENEFIT-EXT trials. Transplantation 2013; 95:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol 2006; 48:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hickson LJ, El-Zoghby ZM, Lorenz EC, et al. Patient survival after kidney transplantation: relationship to pretransplant cardiac troponin T levels. Am J Transplant 2009; 9:1354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Claes K, Bammens B, Evenepoel P, et al. Troponin I is a predictor of acute cardiac events in the immediate postoperative renal transplant period. Transplantation 2010; 89:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaston RS, Kasiske BL, Fieberg AM, et al. Use of cardioprotective medications in kidney transplant recipients. Am J Transplant 2009; 9:1811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pilmore HL, Skeans MA, Snyder JJ, et al. Cardiovascular disease medications after renal transplantation: results from the Patient Outcomes in Renal Transplantation study. Transplantation 2011; 91:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lentine KL, Villines TC, Xiao H, et al. Cardioprotective medication use after acute myocardial infarction in kidney transplant recipients. Transplantation 2011; 91:1120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lentine KL, Naik AS, Schnitzler M, et al. Variation in Comedication Use According to Kidney Transplant Immunosuppressive Regimens: Application of Integrated Registry and Pharmacy Claims Data. Transplant Proc 2016; 48:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lentine KL, Anyaegbu E, Gleisner A, et al. Understanding medical care of transplant recipients through integrated registry and pharmacy claims data. Am J Nephrol 2013; 38:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gill JS, Ma I, Landsberg D, et al. Cardiovascular events and investigation in patients who are awaiting cadaveric kidney transplantation. J Am Soc Nephrol 2005; 16:808.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim WH, Johnson DW, Hawley CM, et al. Impact of Diabetes Mellitus on the Association of Vascular Disease Before Transplantation With Long-term Transplant and Patient Outcomes After Kidney Transplantation: A Population Cohort Study. Am J Kidney Dis 2018; 71:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carpenter MA, John A, Weir MR, et al. BP, cardiovascular disease, and death in the Folic Acid for Vascular Outcome Reduction in Transplantation trial. J Am Soc Nephrol 2014; 25:1554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jardine AG, Holdaas H, Fellström B, et al. fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study. Am J Transplant 2004; 4:988.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lentine KL, Brennan DC. Transplantation: The relevance of the FAVORIT blood pressure associations. Nat Rev Nephrol 2014; 10:366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alhamad T, Brennan DC, Brifkani Z, et al. Pretransplant Midodrine Use: A Newly Identified Risk Marker for Complications After Kidney Transplantation. Transplantation 2016; 100:1086.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Axelrod DA, Cheungpasitporn W, Bunnapradist S, et al. Posttransplant Diabetes Mellitus and Immunosuppression Selection in Older and Obese Kidney Recipients. Kidney Med 2022; 4:100377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fellström B, Jardine AG, Soveri I, et al. Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial. Transplantation 2005; 79:1160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fellström B, Jardine AG, Soveri I, et al. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. Am J Transplant 2005; 5:1986.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiner DE, Park M, Tighiouart H, et al. Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial. Am J Kidney Dis 2019; 73:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lentine KL, Delos Santos R, Axelrod D, et al. Obesity and kidney transplant candidates: how big is too big for transplantation? Am J Nephrol 2012; 36:575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van den Ham EC, Kooman JP, Christiaans MH, van Hooff JP. Relation between steroid dose, body composition and physical activity in renal transplant patients. Transplantation 2000; 69:1591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Vries AP, Bakker SJ, van Son WJ, et al. Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant 2004; 4:1675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Courivaud C, Kazory A, Simula-Faivre D, et al. Metabolic syndrome and atherosclerotic events in renal transplant recipients. Transplantation 2007; 83:1577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meier-Kriesche HU, Arndorfer JA, Kaplan B. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation 2002; 73:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van den Ham EC, Kooman JP, van Hooff JP. Nutritional considerations in renal transplant patients. Blood Purif 2002; 20:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Modanlou KA, Muthyala U, Xiao H, et al. Bariatric surgery among kidney transplant candidates and recipients: analysis of the United States renal data system and literature review. Transplantation 2009; 87:1167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kasiske BL, Klinger D. Cigarette smoking in renal transplant recipients. J Am Soc Nephrol 2000; 11:753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cosio FG, Falkenhain ME, Pesavento TE, et al. Patient survival after renal transplantation: II. The impact of smoking. Clin Transplant 1999; 13:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duerinckx N, Burkhalter H, Engberg SJ, et al. Correlates and Outcomes of Posttransplant Smoking in Solid Organ Transplant Recipients: A Systematic Literature Review and Meta-Analysis. Transplantation 2016; 100:2252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lam NN, Klarenbach S, Quinn RR, et al. Renal Function, Albuminuria, and the Risk of Cardiovascular Events After Kidney Transplantation. Transplant Direct 2018; 4:e389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vanrenterghem Y, Ponticelli C, Morales JM, et al. Prevalence and management of anemia in renal transplant recipients: a European survey. Am J Transplant 2003; 3:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah N, Al-Khoury S, Afzali B, et al. Posttransplantation anemia in adult renal allograft recipients: prevalence and predictors. Transplantation 2006; 81:1112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lentine KL, Schnitzler MA, Abbott KC, et al. Incidence, predictors, and associated outcomes of atrial fibrillation after kidney transplantation. Clin J Am Soc Nephrol 2006; 1:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molnar MZ, Czira M, Ambrus C, et al. Anemia is associated with mortality in kidney-transplanted patients--a prospective cohort study. Am J Transplant 2007; 7:818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamar N, Rostaing L. Negative impact of one-year anemia on long-term patient and graft survival in kidney transplant patients receiving calcineurin inhibitors and mycophenolate mofetil. Transplantation 2008; 85:1120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Guldener C, Stehouwer CD. Homocysteine and methionine metabolism in renal failure. Semin Vasc Med 2005; 5:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chrysant SG, Chrysant GS. The current status of homocysteine as a risk factor for cardiovascular disease: a mini review. Expert Rev Cardiovasc Ther 2018; 16:559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ducloux D, Motte G, Challier B, et al. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J Am Soc Nephrol 2000; 11:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winkelmayer WC, Kramar R, Curhan GC, et al. Fasting plasma total homocysteine levels and mortality and allograft loss in kidney transplant recipients: a prospective study. J Am Soc Nephrol 2005; 16:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bostom AG, Gohh RY, Beaulieu AJ, et al. Treatment of hyperhomocysteinemia in renal transplant recipients. A randomized, placebo-controlled trial. Ann Intern Med 1997; 127:1089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial. Circulation 2011; 123:1763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kang A, Nigwekar SU, Perkovic V, et al. Interventions for lowering plasma homocysteine levels in kidney transplant recipients. Cochrane Database Syst Rev 2015; :CD007910.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pilz S, Meinitzer A, Gaksch M, et al. Homoarginine in the renal and cardiovascular systems. Amino Acids 2015; 47:1703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frenay AR, Kayacelebi AA, Beckmann B, et al. High urinary homoarginine excretion is associated with low rates of all-cause mortality and graft failure in renal transplant recipients. Amino Acids 2015; 47:1827.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merhi B, Shireman T, Carpenter MA, et al. Serum Phosphorus and Risk of Cardiovascular Disease, All-Cause Mortality, or Graft Failure in Kidney Transplant Recipients: An Ancillary Study of the FAVORIT Trial Cohort. Am J Kidney Dis 2017; 70:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Major RW, Cheng MRI, Grant RA, et al. Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis. PLoS One 2018; 13:e0192895.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7314 Version 24.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15615820" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Incidence and predictors of myocardial infarction after kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15367222" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18385393" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Variations in the risk for cerebrovascular events after kidney transplant compared with experience on the waiting list and after graft failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16183428" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : De novo congestive heart failure after kidney transplantation: a common condition with poor prognostic implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22000138" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Prevention of cardiovascular disease in adult recipients of kidney transplants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15216484" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Cardiovascular risk in stage 4 and 5 nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16969281" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Cardiovascular complications after renal transplantation and their prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30472701" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Trends in the Causes of Death among Kidney Transplant Recipients in the United States (1996-2014).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30472701" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Trends in the Causes of Death among Kidney Transplant Recipients in the United States (1996-2014).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26361801" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The changing trends and outcomes in renal replacement therapy: data from the ERA-EDTA Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26985745" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The Risk of Cardiovascular Disease Is Not Increasing Over Time Despite Aging and Higher Comorbidity Burden of Kidney Transplant Recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18294155" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Patient survival and cardiovascular risk after kidney transplantation: the challenge of diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3287917" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Risk factors for accelerated atherosclerosis in renal transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16788687" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Cardiovascular events following renal transplantation: role of traditional and transplant-specific risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16129216" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18212625" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Risk factors for cardiovascular events after successful renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15200454" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Predicting coronary heart disease in renal transplant recipients: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11912270" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12239246" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Graft loss and acute coronary syndromes after renal transplantation in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15168374" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Obesity and kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15458460" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Prognostic value of inducible myocardial ischemia in predicting cardiovascular events after renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19541816" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Inflammation in renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12717218" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21372213" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Low physical activity and risk of cardiovascular and all-cause mortality in renal transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25675199" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Homoarginine and Clinical Outcomes in Renal Transplant Recipients: Results From the Assessment of Lescol in Renal Transplantation Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15996243" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Coronary artery calcification in renal transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15840052" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Clinical impact of preexisting vascular calcifications on mortality after renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16481414" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Acute myocardial infarction and kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18645495" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Obesity and cardiac risk after kidney transplantation: experience at one center and comprehensive literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18165772" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The impact of left ventricular systolic dysfunction on survival after renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16176999" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Comorbid conditions in kidney transplantation: association with graft and patient survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24056622" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Predictors of graft failure and death in elderly kidney transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24056622" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Predictors of graft failure and death in elderly kidney transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11880219" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Hospitalized congestive heart failure after renal transplantation in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12937314" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Early renal insufficiency and hospitalized heart disease after renal transplantation in the era of modern immunosuppression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12694071" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Hospitalized atrial fibrillation after renal transplantation in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25963131" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Body mass index and outcome in renal transplant recipients: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20299337" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Non-invasive detection of pulmonary hypertension prior to renal transplantation is a predictor of increased risk for early graft dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19034007" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Pulmonary hypertension is associated with reduced patient survival after kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23542473" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Do echocardiographic parameters predict mortality in patients with end-stage renal disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26985742" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Evaluation and Management of Pulmonary Hypertension in Kidney Transplant Candidates and Recipients: Concepts and Controversies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30852913" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31582143" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10966499" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Explained and unexplained ischemic heart disease risk after renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18322053" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Cardiovascular outcomes in the outpatient kidney transplant clinic: the Framingham risk score revisited.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20415903" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Predicting coronary heart disease after kidney transplantation: Patient Outcomes in Renal Transplantation (PORT) Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23192156" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : The external validation of the cardiovascular risk equation for renal transplant recipients: applications to BENEFIT and BENEFIT-EXT trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16814641" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Biomarkers in acute cardiac disease: the present and the future.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19459818" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Patient survival after kidney transplantation: relationship to pretransplant cardiac troponin T levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20145526" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Troponin I is a predictor of acute cardiac events in the immediate postoperative renal transplant period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19519808" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Use of cardioprotective medications in kidney transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21301401" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Cardiovascular disease medications after renal transplantation: results from the Patient Outcomes in Renal Transplantation study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21427631" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Cardioprotective medication use after acute myocardial infarction in kidney transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26915843" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Variation in Comedication Use According to Kidney Transplant Immunosuppressive Regimens: Application of Integrated Registry and Pharmacy Claims Data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24216747" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Understanding medical care of transplant recipients through integrated registry and pharmacy claims data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15689406" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Cardiovascular events and investigation in patients who are awaiting cadaveric kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29191625" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Impact of Diabetes Mellitus on the Association of Vascular Disease Before Transplantation With Long-term Transplant and Patient Outcomes After Kidney Transplantation: A Population Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24627349" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : BP, cardiovascular disease, and death in the Folic Acid for Vascular Outcome Reduction in Transplantation trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15147434" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24802067" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Transplantation: The relevance of the FAVORIT blood pressure associations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26950718" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Pretransplant Midodrine Use: A Newly Identified Risk Marker for Complications After Kidney Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35072042" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Posttransplant Diabetes Mellitus and Immunosuppression Selection in Older and Obese Kidney Recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15880062" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15996249" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30037726" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23221167" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Obesity and kidney transplant candidates: how big is too big for transplantation?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10836368" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Relation between steroid dose, body composition and physical activity in renal transplant patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15367224" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17589340" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Metabolic syndrome and atherosclerotic events in renal transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11792981" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11818675" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Nutritional considerations in renal transplant patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19384163" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Bariatric surgery among kidney transplant candidates and recipients: analysis of the United States renal data system and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10752535" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Cigarette smoking in renal transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10485376" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Patient survival after renal transplantation: II. The impact of smoking.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27479162" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Correlates and Outcomes of Posttransplant Smoking in Solid Organ Transplant Recipients: A Systematic Literature Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30498766" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Renal Function, Albuminuria, and the Risk of Cardiovascular Events After Kidney Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12814475" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Prevalence and management of anemia in renal transplant recipients: a European survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16641595" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Posttransplantation anemia in adult renal allograft recipients: prevalence and predictors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17699219" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Incidence, predictors, and associated outcomes of atrial fibrillation after kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17391125" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Anemia is associated with mortality in kidney-transplanted patients--a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18431231" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Negative impact of one-year anemia on long-term patient and graft survival in kidney transplant patients receiving calcineurin inhibitors and mycophenolate mofetil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16047272" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Homocysteine and methionine metabolism in renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29979619" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : The current status of homocysteine as a risk factor for cardiovascular disease: a mini review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10616849" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15563562" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Fasting plasma total homocysteine levels and mortality and allograft loss in kidney transplant recipients: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9412311" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Treatment of hyperhomocysteinemia in renal transplant recipients. A randomized, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21482964" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25938479" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Interventions for lowering plasma homocysteine levels in kidney transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25929587" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Homoarginine in the renal and cardiovascular systems.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26142633" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : High urinary homoarginine excretion is associated with low rates of all-cause mortality and graft failure in renal transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28579423" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Serum Phosphorus and Risk of Cardiovascular Disease, All-Cause Mortality, or Graft Failure in Kidney Transplant Recipients: An Ancillary Study of the FAVORIT Trial Cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29561894" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
